slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,471
Current window 81,631-81,660
Pages 3,950
Rows per page 30
Component
81,631-81,660 of 118,471
90
The slide uses a Q&A transcript format to validate a negative thesis about the viability of H3 receptor programs.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
91
The slide uses a Q&A transcript format to validate the thesis that the H3 receptor class is fundamentally flawed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
93
The slide uses a Q&A format to build a case against the safety of a drug program.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
95
The slide uses expert testimony to establish a precedent of failure in the H3 receptor space, specifically contrasting J&J's robust trials with Bioprojet's pitolisant.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
96
The slide uses a Q&A format to discredit the competitor's R&D rigor.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
100
The slide uses highlighted text to emphasize key quotes from expert interviews.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
103
The slide presents two distinct expert critiques regarding IP expiration and clinical trial quality, attributed to a senior scientist at Johnson & Johnson.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
109
The slide uses a table to contrast initial high-dose trials with subsequent lower-dose trials to imply company knowledge of toxicity.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
111
The slide uses a 'villain critique' style to highlight a lack of transparency in clinical trial reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
112
The slide uses a 'fraud-exposure' narrative to highlight missing safety data in regulatory filings.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
114
The slide uses a critical tone to highlight potential data manipulation or poor reporting practices in a clinical trial publication.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
118
The slide uses a 'black box' argument to challenge the validity of the sponsor's pharmacokinetic model.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
120
The slide uses a combination of narrative argument and a direct quote from a consultant to build a case against the company's transparency.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
121
The slide presents a direct quote from a PK expert to undermine the validity of the company's safety assertions.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
123
The slide uses a red box to highlight a specific data point (40mg dose) in a table to support the argument of inconsistent reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
124
The slide uses a specific FDA review document (NDA 211150) to challenge official plasma level claims.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
126
The slide uses a table to expose data inconsistencies and safety risks, framing the variability as a 'red flag' regarding the drug's safety profile.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
128
The slide uses a direct quote from an FDA clinical review to contradict the company's safety claims, supported by a table of clinical data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
131
The slide uses a quote from a pharmacology consultant to argue that safety margins are overestimated due to drug accumulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
132
The slide highlights a specific discrepancy in an FDA review document (page 32) where the graph title claims 'steady state Cmax' but the underlying data is from a single dose.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
133
The slide uses a red box to highlight the specific column in the table containing the erroneous data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
134
The slide documents the source data used by a consultant to derive a linear regression model for QTc vs. plasma levels.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
135
The slide uses a 'before-after' logic to expose a flaw in regulatory reliance on single-dose data. The red box highlights the critical 'Upper limit TQT' values in the corrected table.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
139
The slide uses a direct excerpt from a package insert to support the argument that dose reduction is required due to drug interactions.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
141
The slide uses direct citations from peer-reviewed papers to validate the consultant's findings.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
143
The slide uses a ClinicalTrials.gov entry as evidence of a 'buried' or incomplete study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
144
The slide uses a Wikipedia table to demonstrate the complexity of CYP2D6 phenotypes to undermine the validity of the FDA's small-sample study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
148
The slide uses a combination of narrative argument and a supporting data table to challenge the safety profile of the drug.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
155
The slide uses a narrative summary followed by a supporting table (Table 4) to challenge the safety reporting of the drug.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
165
The slide uses a 'preempt_rebuttal' strategy by highlighting a specific safety concern (eosinophilic abnormality) that the authors claim was ignored in official FDA review documents.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit